Austin, Texas-based TVA Medical has secured a $15 million financing with new investors Baxter Ventures and Boston Scientific; existing investors Sante Ventures, S3 Ventures, TriStar Technology Ventures; and others.
The investment will fund the continuation of clinical activities and the acceleration of market development for the EverlinQ EndoAVF System.
The system a catheter-based technology designed to create hemodialysis access for chronic kidney disease patients.
The financing will support the novel endovascular access trial clinical study and additional global clinical research. — Michael Cipriano